Thyroid Eye Disease clinical trials at UC Davis

1 research study open to eligible people

TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
open to eligible people ages 18-80
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
Sacramento, California and other locations

Last updated: January 28, 2026